BCL2 and cancer: While the rewiring of the BCL-2 interactome in senescent cells is thought to prime them for apoptosis, the universal use of pro-apoptotic BH3 mimetics as the senolytics of choice in “one-two punch” regimens remains uncertain due to the inconsistent responses observed in TIS cancer cells [20–24].